Phase II Trial of VELCADE (Bortezomib) in Combination with Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients with Newly-diagnosed Glioblastoma Multiforme.
A study for patients with newly-diagnosed Glioblastoma Multiforme using study drug Bortezomib
Sponsor: Jonsson Comprehensive Cancer Center
Enrolling: Male and Female Patients
IRB Number: AAAL6001
U.S. Govt. ID: NCT00998010
Contact: Andrew Lassman: 212-342-0571 /
Additional Study Information: The purpose of this study is to find out whether study drug bortezomib with radiation therapy and Temozolomide is safe when given to patients with brain tumors. This study will also evaluate the side effects and see whether the combination of bortezomib with radiation and Temozolomide can be effective in shrinking tumors. Bortezomib is the investigational therapy being administered in this research study. There is increasing evidence that tumor growth may be the result of the overproduction of certain substances made by the body that function to regulate cell division and cell survival, calledgrowth factors. Bortezomib is a proteasome (protein) inhibitor and its primary mechanism of action is inhibition of the cell growth by inhibiting several pathways which are responsible to regulate cell division and cell survival.
This study is closed
Andrew Lassman, MD
Do You Qualify?
Do you have a confirmed diagnosis of intracranial glioblastoma multiforme or gliosarcoma? Yes No
Have you had a myocardial infarction within the past 6 months? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Andrew Lassman